These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 16543688

  • 21. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 22. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.
    Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T.
    Lancet; 2003 Jan 11; 361(9352):117-24. PubMed ID: 12531578
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 11; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 25. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr 11; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 26. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
    Kosmadakis G, Filiopoulos V, Georgoulias C, Tentolouris N, Michail S.
    Scand J Urol Nephrol; 2010 Sep 11; 44(4):251-6. PubMed ID: 20201749
    [Abstract] [Full Text] [Related]

  • 27. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec 11; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 28. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
    Ruggenenti P, Perna A, Tonelli M, Loriga G, Motterlini N, Rubis N, Ledda F, Rota S, Satta A, Granata A, Battaglia G, Cambareri F, David S, Gaspari F, Stucchi N, Carminati S, Ene-Iordache B, Cravedi P, Remuzzi G, ESPLANADE Study Group.
    Clin J Am Soc Nephrol; 2010 Nov 11; 5(11):1928-38. PubMed ID: 20671225
    [Abstract] [Full Text] [Related]

  • 29. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep 11; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 30. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).
    Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D.
    Am J Kidney Dis; 2014 Feb 11; 63(2):244-50. PubMed ID: 24210590
    [Abstract] [Full Text] [Related]

  • 31. Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease.
    Frimodt-Møller M, Høj Nielsen A, Strandgaard S, Kamper AL.
    Nephrol Dial Transplant; 2010 Mar 11; 25(3):842-7. PubMed ID: 19903661
    [Abstract] [Full Text] [Related]

  • 32. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
    Renke M, Tylicki L, Rutkowski P, Rutkowski B.
    Scand J Urol Nephrol; 2004 Mar 11; 38(5):427-33. PubMed ID: 15764256
    [Abstract] [Full Text] [Related]

  • 33. Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.
    Bandak G, Sang Y, Gasparini A, Chang AR, Ballew SH, Evans M, Arnlov J, Lund LH, Inker LA, Coresh J, Carrero JJ, Grams ME.
    J Am Heart Assoc; 2017 Jul 19; 6(7):. PubMed ID: 28724651
    [Abstract] [Full Text] [Related]

  • 34. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.
    MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.
    Am J Kidney Dis; 2006 Jul 19; 48(1):8-20. PubMed ID: 16797382
    [Abstract] [Full Text] [Related]

  • 35. Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study.
    Wolak T, Aliev E, Rogachev B, Baumfeld Y, Cafri C, Abu-Shakra M, Novack V.
    Isr Med Assoc J; 2013 Nov 19; 15(11):682-7. PubMed ID: 24511648
    [Abstract] [Full Text] [Related]

  • 36. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.
    Clin Exp Nephrol; 2011 Oct 19; 15(5):700-707. PubMed ID: 21625892
    [Abstract] [Full Text] [Related]

  • 37. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
    Gales BJ, Bailey EK, Reed AN, Gales MA.
    Ann Pharmacother; 2010 Feb 19; 44(2):360-6. PubMed ID: 20086184
    [Abstract] [Full Text] [Related]

  • 38. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
    Zhu S, Liu Y, Wang L, Meng QH.
    Nephrol Dial Transplant; 2008 Sep 19; 23(9):2841-6. PubMed ID: 18390891
    [Abstract] [Full Text] [Related]

  • 39. Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis.
    Kitamura N, Matsukawa Y, Takei M, Sawada S.
    J Int Med Res; 2009 Sep 19; 37(3):892-8. PubMed ID: 19589275
    [Abstract] [Full Text] [Related]

  • 40. Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
    Krairittichai U, Sarinnapakorn V, Mahannopkul R, Ainwan P.
    J Med Assoc Thai; 2017 Feb 19; 100 Suppl 1():S40-7. PubMed ID: 29927180
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.